We are a biopharmaceutical company pioneering the application of artificial intelligence and big data analytics integrated with drug development expertise. We use our proprietary platforms to advance the next wave of medicines and significantly improve the clinical and regulatory success of drug development.
Our goal is to develop innovative medicines in immuno-oncology, neuroscience, and rare diseases with high unmet need. We believe that our Research & Development Engine can result in a disruptive change that will impact pharma productivity and innovation to benefit the entire healthcare ecosystem.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. Our drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. We believe that this differentiated approach has the potential to reduce the cost and time of drug development in diseases with substantial unmet medical need.learn More
InveniAI is leading the application of artificial intelligence and machine learning to transform how breakthrough innovation is identified and monitored across industries. As the form and size of data is evolving, we are focused on balancing technology and human expertise to harness only the most relevant alpha signals of innovation.learn More
E.Z. BioXcel, Center of Excellence (CoE) for Research and Development is an innovation hub focused on the development of transformative patient treatments. It houses a rich and diverse cross-functional mix of highly qualified scientific, commercial and medical experts to ensure our partners are able to innovate in an evolving healthcare environment. The center encompasses 100+ years of cumulative drug discovery, development, and management experience in over 100+ indications.
We are leveraging our artificial intelligence and big data capabilities to develop a pipeline of product candidates with a high probability of success in immuno-oncology, neurosciences, and rare diseases. List of development programs of our portfolio companies.
|Therapeutic Area||COMPOUND||INDICATION||IND||Phase I/II||Phase III|
|Immuno-Oncology||BXCL701||Neuroendocrine Prostate Cancer (tNEPC) & Pancreatic Cancer||
|Neuroscience||BXCL501||Geriatric Dementia & Schizophrenia/Bipolar||
|Orphan & Rare Diseases||BXCL901||Hematology/Oncology||
BioXcel has a special interest in the following disease categories, where we have deep in-house expertise:
BioXcel’s partnerships are focused on the discovery and ideation of innovative drug candidates with a risk mitigated profile and improved probability of clinical and commercial success. Our partnerships are focused on de-novo drug discovery, drug re-innovation, asset rescue, indication expansion, life-cycle management, and product reformulation opportunities.
BioXcel Featured in Fierce Biotech The recent uptick in interest in drug repurposing, the popularity of which ebbs and flows, could give the team a tailwind. Astellas Pharma has struck a clutch of deals since making repurposing a cornerstone of... Read More
By Peter Winter | BioWorld Insight Editor CBiotechnology is no stranger to the creation and analysis of large amounts of data, whether it is "-omics" in nature or from patients in clinical trials. However, having access to masses of datasets... Read More
https://www.youtube.com/watch?v=QDaLoFqPesw Read More
(more…) Read More
BALTIMORE--(BUSINESS WIRE)-- Centrexion Therapeutics, a company focused on advancing chronic pain treatment with new non-opioid and non-surgical therapies, today announced the expansion of its proprietary pipeline with the acquisition of three new analgesic candidates from Boehringer Ingelheim. The company’s proprietary... Read More
BioXcel Corporation has announced the launch of its first-in-class PharmGPS Oncology and Immuno-Oncology Suite, which uses big data technology to help biopharmaceutical companies and other stakeholders identify and prioritize the those immunotherapy candidates in their portfolios with the best... Read More
BioXcel said today it has joined with Takeda Pharmaceutical’s U.S.-based global development group to repurpose compounds into new treatments for rare diseases. The value of the partnership was not disclosed. BioXcel said the expertise of its Big Data Innovation Lab... Read More
http://www.raredr.com/articles/Q-A-BioXcel-Orphan-Drug-Suite Bioxcel’s popularity grew exponentially following the recent news that Alexion Pharmaceuticals is using their platform “Orphan Drug Suite” to assist the orphan drug company in developing and/or discovering new treatments. In this exclusive interview with Rare Disease Report (RDR),... Read More
FierceBiotechIT January 30, 2015 | By Nick Paul Taylor Alexion Pharmaceuticals ($ALXN) has turned to Big Data specialist BioXcel for help identifying its next blockbuster rare disease drug. BioXcel is applying its rare disease database to the collaboration, which aims... Read More
This video interview may include forward-looking statements that involve risks and uncertainties. Forward- looking statements are statements that are not historical facts and are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements.... Read More
Biotechnology is no stranger to the creation and analysis of large amounts of data, whether it is "-omics" in nature or from patients in clinical trials. However, having access to masses of datasets is only a good starting point; sooner... Read More